Related Experiment Video
Updated: Jun 9, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Potential Therapeutic Targets for the Treatment of HPV-Associated Malignancies
Ziyao Lu1, Shahab Haghollahi1, Muhammad Afzal1
1Dartmouth Cancer Center, Manchester, NH 03104, USA.
Abstract:
This review article aims to summarize broadly recent developments in the treatment of HPV-associated cancers, including cervical cancer and head and neck squamous cell carcinoma. Relatively new treatments targeting the key HPV E6 and E7 oncoproteins, including gene editing with TALENs and CRISPR/Cas9, are discussed. Given the increased immunogenicity of HPV-related diseases, other therapies such as PRR agonists, adoptive cell transfer, and tumor vaccines are reaching the clinical trial phase. Due to the mechanism, immunogenicity, and reversibility of HPV carcinogenesis, HPV-related cancers present unique targets for current and future therapies.
Insights
Recent advancements in treating human papillomavirus (HPV)-associated cancers involve novel therapies targeting HPV oncoproteins and leveraging the immune system. These innovative treatments offer unique opportunities for managing HPV-related malignancies.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Human papillomavirus (HPV) is a significant cause of several cancers, including cervical cancer and head and neck squamous cell carcinoma.
- Current treatment strategies for HPV-associated cancers are evolving, with a focus on targeted therapies and immunomodulation.
Purpose of the Study:
- To review recent therapeutic developments for HPV-associated cancers.
- To highlight novel treatment modalities targeting key HPV oncoproteins and immune responses.
Main Methods:
- Review of recent scientific literature on HPV-associated cancer treatments.
- Discussion of gene-editing technologies (TALENs, CRISPR/Cas9) targeting HPV E6 and E7 oncoproteins.
- Exploration of immunotherapies including PRR agonists, adoptive cell transfer, and tumor vaccines.
Main Results:
- Emerging therapies show promise in targeting the specific mechanisms of HPV-driven carcinogenesis.
- Gene editing offers a precise approach to disable viral oncogenes.
- Immunotherapeutic strategies are advancing towards clinical trials, capitalizing on the immunogenicity of HPV-related diseases.
Conclusions:
- HPV-associated cancers present unique therapeutic targets due to their distinct carcinogenic mechanisms.
- Novel treatments, including gene editing and advanced immunotherapies, are poised to improve patient outcomes.
- The reversibility and immunogenicity of HPV carcinogenesis offer distinct opportunities for innovative therapeutic interventions.
More Related Videos
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
13:56A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
Published on: July 18, 2013
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Mitogens and the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation